data_1b1a_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1b1a _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -158.89 164.0 36.08 Favored 'General case' 0 C--N 1.35 0.589 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.41 ' HD3' ' H ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -76.14 -169.75 1.23 Allowed 'General case' 0 C--N 1.346 0.456 0 CA-C-N 111.43 -2.623 . . . . 0.0 104.649 177.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -76.61 -179.52 5.33 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 m -150.12 94.4 2.14 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 101.629 -3.471 . . . . 0.0 101.629 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 34' ' ' VAL . 49.8 pt -122.74 158.63 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-N 109.24 -3.618 . . . . 0.0 105.763 -175.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 34.8 t -149.99 165.47 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 CA-C-N 111.026 -2.806 . . . . 0.0 106.214 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -141.46 119.21 11.76 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 102.154 -3.276 . . . . 0.0 102.154 177.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.61 178.23 48.72 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 112.834 -1.985 . . . . 0.0 112.512 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . 0.291 43.7 t 64.09 -106.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 111.757 -2.221 . . . . 0.0 109.538 -178.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.4 pt -154.59 113.67 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.595 0 N-CA-C 105.677 -1.972 . . . . 0.0 105.677 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -96.46 -105.63 2.24 Favored Glycine 0 C--N 1.352 1.441 0 CA-C-N 112.361 -2.2 . . . . 0.0 109.916 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.3 t -161.11 159.21 28.82 Favored 'General case' 0 C--N 1.351 0.637 0 N-CA-C 106.014 -1.846 . . . . 0.0 106.014 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -149.54 100.72 3.02 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 110.782 -2.917 . . . . 0.0 103.222 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.456 ' H ' HD12 ' A' ' 22' ' ' ILE . 27.4 p -82.58 88.51 6.66 Favored 'General case' 0 C--N 1.354 0.764 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 -179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' HIS . . . . . . . . . . . . . 73.3 t60 -134.25 -50.74 0.81 Allowed 'General case' 0 C--N 1.346 0.452 0 CA-C-N 111.583 -2.553 . . . . 0.0 104.393 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.56 41.37 1.73 Allowed 'General case' 0 C--N 1.35 0.626 0 N-CA-C 105.02 -2.215 . . . . 0.0 105.02 179.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 44.3 t -135.87 -51.74 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.851 0 CA-C-N 113.367 -1.742 . . . . 0.0 108.683 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 73.91 101.8 0.08 OUTLIER Glycine 0 C--N 1.354 1.546 0 CA-C-N 113.747 -1.57 . . . . 0.0 110.15 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -145.94 -165.52 2.22 Favored 'General case' 0 C--N 1.353 0.741 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 -178.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -123.39 90.85 3.36 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 102.72 -3.067 . . . . 0.0 102.72 178.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.456 HD12 ' H ' ' A' ' 15' ' ' CYS . 4.1 pt -140.68 -41.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.702 0 CA-C-N 113.38 -1.736 . . . . 0.0 106.594 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.9 mt -108.67 70.86 0.76 Allowed 'General case' 0 C--N 1.352 0.715 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -93.15 -49.81 5.81 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-N 112.915 -1.948 . . . . 0.0 106.815 -178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -145.88 -43.98 0.21 Allowed 'General case' 0 C--N 1.35 0.608 0 CA-C-N 113.308 -1.769 . . . . 0.0 106.535 -179.033 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -134.22 168.35 19.02 Favored 'General case' 0 C--N 1.352 0.703 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 8.8 t80 133.68 -52.83 0.01 OUTLIER 'General case' 0 C--N 1.355 0.816 0 CA-C-N 110.645 -2.98 . . . . 0.0 103.691 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.62 -12.67 0.11 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 112.476 -2.147 . . . . 0.0 106.932 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -79.5 0.65 28.77 Favored 'General case' 0 CA--C 1.554 1.125 0 N-CA-C 105.281 -2.118 . . . . 0.0 105.281 176.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.2 -52.78 4.22 Favored 'General case' 0 C--N 1.365 1.243 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 128.66 17.02 1.96 Allowed Glycine 0 CA--C 1.537 1.459 0 CA-C-N 111.438 -2.619 . . . . 0.0 114.0 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -64.16 165.33 9.41 Favored 'General case' 0 C--N 1.358 0.958 0 CA-C-O 123.179 1.466 . . . . 0.0 108.992 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -89.91 79.8 6.55 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-N 110.629 -2.987 . . . . 0.0 104.113 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 6' ' ' ILE . 11.7 t -100.74 134.44 40.67 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 113.948 -1.478 . . . . 0.0 113.676 -178.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.1 t -120.29 145.89 25.95 Favored 'Isoleucine or valine' 0 C--N 1.352 0.687 0 CA-C-N 110.462 -3.063 . . . . 0.0 105.113 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 53.2 t-20 -127.28 92.85 3.59 Favored 'General case' 0 C--N 1.346 0.423 0 N-CA-C 102.855 -3.017 . . . . 0.0 102.855 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 tt -85.76 142.33 13.31 Favored 'Isoleucine or valine' 0 C--N 1.351 0.667 0 CA-C-N 112.211 -2.268 . . . . 0.0 106.442 -178.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.67 -173.88 1.03 Allowed Glycine 0 C--N 1.354 1.534 0 CA-C-N 111.219 -2.719 . . . . 0.0 114.574 -178.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.1 m -46.57 164.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.771 0 CA-C-N 110.402 -2.899 . . . . 0.0 113.21 -178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.403 ' H ' HD12 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -67.5 136.84 55.22 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 111.173 -2.74 . . . . 0.0 107.32 -179.698 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 60.4 p -139.36 -170.59 0.24 Allowed Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 102.941 -2.985 . . . . 0.0 102.941 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -56.79 141.24 92.52 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 122.033 1.822 . . . . 0.0 107.383 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -72.7 -16.34 61.68 Favored 'General case' 0 C--N 1.348 0.528 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.312 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 21.3 mm-40 -84.13 -23.09 30.83 Favored 'General case' 0 CA--C 1.55 0.943 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -90.64 -22.67 6.22 Favored 'Isoleucine or valine' 0 C--N 1.348 0.542 0 CA-C-N 113.622 -1.626 . . . . 0.0 108.759 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -87.06 -15.68 37.84 Favored 'General case' 0 C--N 1.359 0.998 0 N-CA-C 104.543 -2.391 . . . . 0.0 104.543 179.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -76.84 -41.26 32.51 Favored 'Isoleucine or valine' 0 C--N 1.36 1.032 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -70.6 -35.0 72.77 Favored 'General case' 0 C--N 1.352 0.705 0 CA-C-N 113.739 -1.573 . . . . 0.0 106.806 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -75.85 -9.4 58.57 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.138 -2.301 . . . . 0.0 107.416 178.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.23 -17.3 27.74 Favored 'General case' 0 C--N 1.364 1.21 0 O-C-N 123.816 0.697 . . . . 0.0 109.948 178.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mp -66.24 -44.88 91.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 N-CA-C 104.275 -2.491 . . . . 0.0 104.275 178.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -77.26 -47.35 20.35 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.015 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.54 ' C ' ' H ' ' A' ' 55' ' ' ALA . 4.6 m -90.51 56.08 3.21 Favored 'General case' 0 C--N 1.356 0.88 0 C-N-CA 126.279 1.831 . . . . 0.0 106.842 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -89.52 29.13 1.17 Allowed 'General case' 0 CA--C 1.551 1.01 0 CA-C-N 113.273 -1.785 . . . . 0.0 106.985 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.54 ' H ' ' C ' ' A' ' 53' ' ' THR . . . -63.79 126.66 28.34 Favored 'General case' 0 CA--C 1.493 -1.234 0 C-N-CA 131.275 3.83 . . . . 0.0 106.108 177.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -62.84 -10.78 14.44 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 111.065 -2.789 . . . . 0.0 106.552 177.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -136.06 140.71 43.99 Favored 'General case' 0 C--N 1.372 1.578 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 6.9 mt -149.53 80.95 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 104.698 -2.334 . . . . 0.0 104.698 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.438 ' CD1' ' HA3' ' A' ' 126' ' ' GLY . 9.3 tt -81.89 99.22 8.93 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 178.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 1.1 mp -83.22 96.43 8.45 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.82 80.35 7.31 Favored 'General case' 0 C--N 1.351 0.672 0 CA-C-N 110.772 -2.922 . . . . 0.0 103.202 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.4 t -95.71 139.97 31.18 Favored 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 110.812 -2.904 . . . . 0.0 107.501 -175.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 11.2 mp -108.82 56.3 0.62 Allowed 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 110.484 -3.053 . . . . 0.0 105.429 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 66.32 95.57 0.06 Allowed 'General case' 0 C--N 1.357 0.897 0 CA-C-N 112.606 -2.088 . . . . 0.0 107.867 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 177.7 137.41 2.74 Favored Glycine 0 C--N 1.353 1.492 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.539 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' A' ' 67' ' ' GLY . 19.4 tt0 92.31 172.73 0.02 OUTLIER 'General case' 0 C--N 1.358 0.957 0 N-CA-C 105.258 -2.127 . . . . 0.0 105.258 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.411 ' H ' ' HG2' ' A' ' 66' ' ' GLN . . . -54.05 98.32 0.04 OUTLIER Glycine 0 C--N 1.359 1.808 0 O-C-N 124.566 1.166 . . . . 0.0 112.71 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 46.85 54.14 9.46 Favored 'General case' 0 C--N 1.361 1.07 0 N-CA-C 105.172 -2.159 . . . . 0.0 105.172 -178.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.546 ' CG2' ' H ' ' A' ' 70' ' ' ASP . 20.1 mm 75.87 -152.65 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.235 0 N-CA-C 103.441 -2.8 . . . . 0.0 103.441 -176.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.546 ' H ' ' CG2' ' A' ' 69' ' ' ILE . 7.2 m-20 -101.03 31.35 3.65 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 104.62 -2.363 . . . . 0.0 104.62 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.11 -67.67 0.84 Allowed 'General case' 0 C--N 1.352 0.696 0 N-CA-C 104.265 -2.495 . . . . 0.0 104.265 -176.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -76.8 -31.45 56.96 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 116.511 -2.075 . . . . 0.0 105.428 177.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -65.53 -76.7 0.31 Allowed Glycine 0 C--N 1.358 1.772 0 C-N-CA 118.506 -1.807 . . . . 0.0 113.381 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 15.4 mt -82.05 -25.15 34.87 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 116.382 -1.771 . . . . 0.0 111.235 -175.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.557 HH21 ' CG ' ' A' ' 114' ' ' ASP . 0.1 OUTLIER -71.09 -28.82 64.61 Favored 'General case' 0 C--N 1.364 1.198 0 C-N-CA 111.996 -3.882 . . . . 0.0 108.672 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 21.3 mm100 -63.53 -30.18 71.34 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 117.835 -1.546 . . . . 0.0 107.476 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 27.7 mmmt -69.27 -42.54 75.42 Favored 'General case' 0 C--N 1.36 1.033 0 O-C-N 124.584 1.177 . . . . 0.0 108.714 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' CYS . . . . . . . . . . . . . 86.8 m -58.49 -36.02 73.11 Favored 'General case' 0 C--N 1.348 0.527 0 C-N-CA 126.49 1.916 . . . . 0.0 108.436 -178.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -72.41 -47.94 45.21 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -90.13 24.84 2.35 Favored 'General case' 0 C--N 1.361 1.077 0 O-C-N 124.488 1.118 . . . . 0.0 111.132 -178.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -111.53 -65.59 1.16 Allowed 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 178.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 167.68 -22.92 0.11 Allowed Glycine 0 CA--C 1.532 1.156 0 CA-C-N 111.339 -2.664 . . . . 0.0 112.759 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 46.64 48.13 14.47 Favored 'General case' 0 C--N 1.364 1.229 0 C-N-CA 125.764 1.626 . . . . 0.0 108.726 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -63.45 -98.98 0.0 OUTLIER 'General case' 0 C--N 1.351 0.646 0 CA-C-N 112.149 -2.296 . . . . 0.0 106.845 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.67 -18.4 48.34 Favored Glycine 0 CA--C 1.536 1.397 0 CA-C-N 114.6 -1.182 . . . . 0.0 110.298 178.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 mt -60.72 106.59 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 124.117 1.913 . . . . 0.0 109.392 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.5 pp -104.61 131.45 52.01 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 108.725 -3.852 . . . . 0.0 102.12 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.412 ' O ' ' HA ' ' A' ' 114' ' ' ASP . 2.5 tt -105.14 126.12 51.74 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 103.481 -2.785 . . . . 0.0 103.481 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . 0.422 ' CE1' ' HB2' ' A' ' 133' ' ' ASP . 1.3 m-30 -121.47 162.42 20.52 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 102.238 -3.245 . . . . 0.0 102.238 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 33.2 t -134.01 167.87 25.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 112.335 -2.211 . . . . 0.0 106.726 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 177.28 -158.54 24.14 Favored Glycine 0 C--N 1.343 0.932 0 C-N-CA 117.706 -2.188 . . . . 0.0 110.436 178.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.88 -112.77 4.07 Favored Glycine 0 C--N 1.35 1.361 0 CA-C-N 112.333 -1.934 . . . . 0.0 108.55 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 21.3 m120 67.97 -179.88 0.23 Allowed 'General case' 0 C--N 1.354 0.771 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 178.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.0 mp -134.61 -96.82 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.352 0.678 0 N-CA-C 104.684 -2.339 . . . . 0.0 104.684 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.8 m -81.61 92.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.358 0.937 0 CA-C-O 122.76 1.267 . . . . 0.0 110.152 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.34 -124.26 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.76 0 CA-C-N 111.669 -2.514 . . . . 0.0 109.115 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 97.8 -51.51 1.33 Allowed Glycine 0 C--N 1.352 1.441 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.419 ' HZ3' ' HB2' ' A' ' 98' ' ' LYS . 10.1 mtmp? -97.85 71.59 2.21 Favored 'General case' 0 C--N 1.352 0.703 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLN . . . . . . . . . . . . . 16.2 tt0 -152.61 27.98 0.55 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 111.837 -2.438 . . . . 0.0 105.491 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -160.09 52.28 0.33 Allowed 'General case' 0 C--N 1.352 0.683 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' TRP . . . . . . . . . . . . . 3.7 t-105 -172.95 -54.03 0.0 OUTLIER Pre-proline 0 N--CA 1.446 -0.634 0 CA-C-N 111.364 -2.653 . . . . 0.0 107.322 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.415 ' C ' ' H ' ' A' ' 104' ' ' VAL . 52.9 Cg_exo -43.92 105.6 0.07 OUTLIER 'Trans proline' 0 C--N 1.39 2.732 0 C-N-CA 122.319 2.013 . . . . 0.0 109.497 -175.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -77.64 1.15 20.64 Favored 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 111.648 -2.524 . . . . 0.0 109.687 -177.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.415 ' H ' ' C ' ' A' ' 102' ' ' PRO . 6.7 p -90.33 -48.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.35 0.624 0 C-N-CA 129.641 3.177 . . . . 0.0 110.847 -178.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -77.31 -42.46 36.76 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 104.03 -2.581 . . . . 0.0 104.03 178.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.45 -15.24 63.56 Favored 'General case' 0 C--N 1.357 0.905 0 CA-C-N 110.962 -2.835 . . . . 0.0 105.618 177.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 30.3 tpt180 -70.61 -47.51 59.79 Favored 'General case' 0 C--N 1.371 1.516 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -83.29 4.79 25.6 Favored 'General case' 0 C--N 1.362 1.117 0 O-C-N 125.741 1.901 . . . . 0.0 111.304 -174.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.415 ' HG2' HH11 ' A' ' 115' ' ' ARG . 32.9 ttpt -90.0 -57.56 2.81 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -177.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.62 -15.5 54.44 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 111.868 -2.424 . . . . 0.0 106.677 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . 0.317 32.6 mmt -88.08 -14.52 38.67 Favored 'General case' 0 C--N 1.372 1.567 0 O-C-N 124.09 0.869 . . . . 0.0 109.608 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -147.37 -89.82 0.09 OUTLIER Glycine 0 C--N 1.348 1.199 0 C-N-CA 118.598 -1.763 . . . . 0.0 110.598 179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -158.9 -25.45 0.07 Allowed 'General case' 0 N--CA 1.433 -1.281 0 CA-C-N 111.221 -2.489 . . . . 0.0 110.953 -175.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.557 ' CG ' HH21 ' A' ' 75' ' ' ARG . 9.1 t70 -53.2 89.94 0.01 OUTLIER 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 126.156 2.884 . . . . 0.0 111.194 -175.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.415 HH11 ' HG2' ' A' ' 109' ' ' LYS . 0.2 OUTLIER -106.29 172.08 7.0 Favored 'General case' 0 C--N 1.328 -0.366 2 CA-C-N 104.43 -5.804 . . . . 0.0 102.426 176.989 . . . . . . . . 4 4 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.17 138.83 14.91 Favored 'Isoleucine or valine' 0 C--N 1.35 0.621 0 C-N-CA 118.336 -1.346 . . . . 0.0 110.478 -177.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' TYR . . . . . 0.508 ' HH ' ' HZ1' ' A' ' 132' ' ' LYS . 59.4 m-85 -138.57 107.4 5.96 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-N 113.509 -1.678 . . . . 0.0 106.848 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -123.22 152.53 64.01 Favored Pre-proline 0 C--N 1.349 0.559 0 CA-C-N 111.364 -2.653 . . . . 0.0 104.646 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_exo -39.14 113.66 0.17 Allowed 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 124.545 3.497 . . . . 0.0 110.24 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.97 -20.33 2.32 Favored Glycine 0 CA--C 1.538 1.527 0 CA-C-N 110.299 -3.137 . . . . 0.0 108.948 -177.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . 0.253 3.2 p -79.02 163.9 57.73 Favored Pre-proline 0 CA--C 1.554 1.132 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -49.71 168.47 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.161 0 C-N-CA 124.581 3.521 . . . . 0.0 111.284 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -66.06 -14.38 44.18 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 121.92 1.747 . . . . 0.0 109.983 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -128.1 68.04 1.35 Allowed 'General case' 0 C--N 1.351 0.672 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 177.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.448 ' C ' ' H ' ' A' ' 127' ' ' ILE . 21.5 m -42.62 -123.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.104 0 C-N-CA 129.867 3.267 . . . . 0.0 111.411 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 59' ' ' LEU . . . -69.3 22.02 0.38 Allowed Glycine 0 CA--C 1.548 2.11 0 CA-C-N 115.088 -0.96 . . . . 0.0 114.271 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.448 ' H ' ' C ' ' A' ' 125' ' ' VAL . 50.1 mt -90.21 -64.59 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 C-N-CA 127.371 2.268 . . . . 0.0 107.245 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -75.48 -16.32 60.32 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 122.657 1.218 . . . . 0.0 108.647 -178.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 125' ' ' VAL 0.278 2.1 m-20 -81.68 -50.84 8.83 Favored 'General case' 0 N--CA 1.436 -1.155 0 C-N-CA 128.278 2.631 . . . . 0.0 107.784 -179.335 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 3.8 pp -62.34 -20.39 64.32 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 117.821 -1.552 . . . . 0.0 108.717 178.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 8.5 tmtm? -80.45 -27.64 37.88 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 113.554 -1.657 . . . . 0.0 108.265 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.508 ' HZ1' ' HH ' ' A' ' 117' ' ' TYR . 1.9 mtpm? -67.25 -54.34 21.85 Favored 'General case' 0 C--N 1.356 0.889 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.422 ' HB2' ' CE1' ' A' ' 89' ' ' TYR 0.273 2.2 m-20 -74.3 -7.0 51.26 Favored 'General case' 0 C--N 1.357 0.911 0 CA-C-N 113.281 -1.782 . . . . 0.0 110.621 -176.848 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 53.0 tp -87.29 -30.53 20.8 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 176.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -90.18 4.07 51.58 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 114.361 -1.29 . . . . 0.0 109.608 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 56.8 mt -145.98 50.64 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 . . . . . 0 C--N 1.353 0.756 0 CA-C-N 113.391 -1.731 . . . . 0.0 111.87 -179.05 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -158.89 164.0 36.08 Favored 'General case' 0 C--N 1.35 0.589 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.483 ' HD3' ' H ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -76.14 -169.75 1.23 Allowed 'General case' 0 C--N 1.346 0.456 0 CA-C-N 111.43 -2.623 . . . . 0.0 104.649 177.912 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -76.61 -179.52 5.33 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 m -150.12 94.4 2.14 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 101.629 -3.471 . . . . 0.0 101.629 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.662 HG13 HG22 ' A' ' 34' ' ' VAL . 49.8 pt -122.74 158.63 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-N 109.24 -3.618 . . . . 0.0 105.763 -175.207 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.504 HG22 ' HB ' ' A' ' 35' ' ' VAL . 34.8 t -149.99 165.47 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 CA-C-N 111.026 -2.806 . . . . 0.0 106.214 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -141.46 119.21 11.76 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 102.154 -3.276 . . . . 0.0 102.154 177.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.61 178.23 48.72 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 112.834 -1.985 . . . . 0.0 112.512 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.668 HG11 ' HA ' ' A' ' 62' ' ' SER 0.291 43.7 t 64.09 -106.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 111.757 -2.221 . . . . 0.0 109.538 -178.818 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.451 HG12 HG12 ' A' ' 10' ' ' VAL . 3.4 pt -154.59 113.67 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.595 0 N-CA-C 105.677 -1.972 . . . . 0.0 105.677 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -96.46 -105.63 2.24 Favored Glycine 0 C--N 1.352 1.441 0 CA-C-N 112.361 -2.2 . . . . 0.0 109.916 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.3 t -161.11 159.21 28.82 Favored 'General case' 0 C--N 1.351 0.637 0 N-CA-C 106.014 -1.846 . . . . 0.0 106.014 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -149.54 100.72 3.02 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 110.782 -2.917 . . . . 0.0 103.222 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.445 ' H ' HD11 ' A' ' 22' ' ' ILE . 27.4 p -82.58 88.51 6.66 Favored 'General case' 0 C--N 1.354 0.764 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 -179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' HIS . . . . . . . . . . . . . 73.3 t60 -134.25 -50.74 0.81 Allowed 'General case' 0 C--N 1.346 0.452 0 CA-C-N 111.583 -2.553 . . . . 0.0 104.393 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.56 41.37 1.73 Allowed 'General case' 0 C--N 1.35 0.626 0 N-CA-C 105.02 -2.215 . . . . 0.0 105.02 179.018 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 44.3 t -135.87 -51.74 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.851 0 CA-C-N 113.367 -1.742 . . . . 0.0 108.683 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 73.91 101.8 0.08 OUTLIER Glycine 0 C--N 1.354 1.546 0 CA-C-N 113.747 -1.57 . . . . 0.0 110.15 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -145.94 -165.52 2.22 Favored 'General case' 0 C--N 1.353 0.741 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 -178.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -123.39 90.85 3.36 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 102.72 -3.067 . . . . 0.0 102.72 178.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.445 HD11 ' H ' ' A' ' 15' ' ' CYS . 4.1 pt -140.68 -41.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.702 0 CA-C-N 113.38 -1.736 . . . . 0.0 106.594 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.9 mt -108.67 70.86 0.76 Allowed 'General case' 0 C--N 1.352 0.715 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -93.15 -49.81 5.81 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-N 112.915 -1.948 . . . . 0.0 106.815 -178.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -145.88 -43.98 0.21 Allowed 'General case' 0 C--N 1.35 0.608 0 CA-C-N 113.308 -1.769 . . . . 0.0 106.535 -179.033 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -134.22 168.35 19.02 Favored 'General case' 0 C--N 1.352 0.703 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.512 ' O ' HG21 ' A' ' 34' ' ' VAL . 8.8 t80 133.68 -52.83 0.01 OUTLIER 'General case' 0 C--N 1.355 0.816 0 CA-C-N 110.645 -2.98 . . . . 0.0 103.691 -179.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.436 ' H ' ' H ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -155.62 -12.67 0.11 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 112.476 -2.147 . . . . 0.0 106.932 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.436 ' H ' ' H ' ' A' ' 28' ' ' THR . 47.6 t30 -79.5 0.65 28.77 Favored 'General case' 0 CA--C 1.554 1.125 0 N-CA-C 105.281 -2.118 . . . . 0.0 105.281 176.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.2 -52.78 4.22 Favored 'General case' 0 C--N 1.365 1.243 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 128.66 17.02 1.96 Allowed Glycine 0 CA--C 1.537 1.459 0 CA-C-N 111.438 -2.619 . . . . 0.0 114.0 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -64.16 165.33 9.41 Favored 'General case' 0 C--N 1.358 0.958 0 CA-C-O 123.179 1.466 . . . . 0.0 108.992 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -89.91 79.8 6.55 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-N 110.629 -2.987 . . . . 0.0 104.113 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.662 HG22 HG13 ' A' ' 6' ' ' ILE . 11.7 t -100.74 134.44 40.67 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 113.948 -1.478 . . . . 0.0 113.676 -178.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.504 ' HB ' HG22 ' A' ' 7' ' ' VAL . 10.1 t -120.29 145.89 25.95 Favored 'Isoleucine or valine' 0 C--N 1.352 0.687 0 CA-C-N 110.462 -3.063 . . . . 0.0 105.113 176.04 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 53.2 t-20 -127.28 92.85 3.59 Favored 'General case' 0 C--N 1.346 0.423 0 N-CA-C 102.855 -3.017 . . . . 0.0 102.855 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 tt -85.76 142.33 13.31 Favored 'Isoleucine or valine' 0 C--N 1.351 0.667 0 CA-C-N 112.211 -2.268 . . . . 0.0 106.442 -178.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.67 -173.88 1.03 Allowed Glycine 0 C--N 1.354 1.534 0 CA-C-N 111.219 -2.719 . . . . 0.0 114.574 -178.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.1 m -46.57 164.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.771 0 CA-C-N 110.402 -2.899 . . . . 0.0 113.21 -178.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.55 ' H ' HD13 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -67.5 136.84 55.22 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 111.173 -2.74 . . . . 0.0 107.32 -179.698 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 60.4 p -139.36 -170.59 0.24 Allowed Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 102.941 -2.985 . . . . 0.0 102.941 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -56.79 141.24 92.52 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 122.033 1.822 . . . . 0.0 107.383 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -72.7 -16.34 61.68 Favored 'General case' 0 C--N 1.348 0.528 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.312 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 21.3 mm-40 -84.13 -23.09 30.83 Favored 'General case' 0 CA--C 1.55 0.943 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -90.64 -22.67 6.22 Favored 'Isoleucine or valine' 0 C--N 1.348 0.542 0 CA-C-N 113.622 -1.626 . . . . 0.0 108.759 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.43 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 0.1 OUTLIER -87.06 -15.68 37.84 Favored 'General case' 0 C--N 1.359 0.998 0 N-CA-C 104.543 -2.391 . . . . 0.0 104.543 179.113 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -76.84 -41.26 32.51 Favored 'Isoleucine or valine' 0 C--N 1.36 1.032 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -70.6 -35.0 72.77 Favored 'General case' 0 C--N 1.352 0.705 0 CA-C-N 113.739 -1.573 . . . . 0.0 106.806 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.43 ' HB3' ' HA ' ' A' ' 46' ' ' PHE . . . -75.85 -9.4 58.57 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.138 -2.301 . . . . 0.0 107.416 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.23 -17.3 27.74 Favored 'General case' 0 C--N 1.364 1.21 0 O-C-N 123.816 0.697 . . . . 0.0 109.948 178.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mp -66.24 -44.88 91.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 N-CA-C 104.275 -2.491 . . . . 0.0 104.275 178.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -77.26 -47.35 20.35 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.015 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.533 ' C ' ' H ' ' A' ' 55' ' ' ALA . 4.6 m -90.51 56.08 3.21 Favored 'General case' 0 C--N 1.356 0.88 0 C-N-CA 126.279 1.831 . . . . 0.0 106.842 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -89.52 29.13 1.17 Allowed 'General case' 0 CA--C 1.551 1.01 0 CA-C-N 113.273 -1.785 . . . . 0.0 106.985 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.533 ' H ' ' C ' ' A' ' 53' ' ' THR . . . -63.79 126.66 28.34 Favored 'General case' 0 CA--C 1.493 -1.234 0 C-N-CA 131.275 3.83 . . . . 0.0 106.108 177.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -62.84 -10.78 14.44 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 111.065 -2.789 . . . . 0.0 106.552 177.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -136.06 140.71 43.99 Favored 'General case' 0 C--N 1.372 1.578 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 6.9 mt -149.53 80.95 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 104.698 -2.334 . . . . 0.0 104.698 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.454 ' CD1' ' HA3' ' A' ' 126' ' ' GLY . 9.3 tt -81.89 99.22 8.93 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 178.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.428 ' CD2' HD12 ' A' ' 74' ' ' LEU . 1.1 mp -83.22 96.43 8.45 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.82 80.35 7.31 Favored 'General case' 0 C--N 1.351 0.672 0 CA-C-N 110.772 -2.922 . . . . 0.0 103.202 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.668 ' HA ' HG11 ' A' ' 10' ' ' VAL . 29.4 t -95.71 139.97 31.18 Favored 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 110.812 -2.904 . . . . 0.0 107.501 -175.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 11.2 mp -108.82 56.3 0.62 Allowed 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 110.484 -3.053 . . . . 0.0 105.429 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 66.32 95.57 0.06 Allowed 'General case' 0 C--N 1.357 0.897 0 CA-C-N 112.606 -2.088 . . . . 0.0 107.867 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 177.7 137.41 2.74 Favored Glycine 0 C--N 1.353 1.492 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.539 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.452 ' HG2' ' H ' ' A' ' 67' ' ' GLY . 19.4 tt0 92.31 172.73 0.02 OUTLIER 'General case' 0 C--N 1.358 0.957 0 N-CA-C 105.258 -2.127 . . . . 0.0 105.258 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.452 ' H ' ' HG2' ' A' ' 66' ' ' GLN . . . -54.05 98.32 0.04 OUTLIER Glycine 0 C--N 1.359 1.808 0 O-C-N 124.566 1.166 . . . . 0.0 112.71 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.401 ' O ' ' HB3' ' A' ' 71' ' ' CYS . 83.6 mt-10 46.85 54.14 9.46 Favored 'General case' 0 C--N 1.361 1.07 0 N-CA-C 105.172 -2.159 . . . . 0.0 105.172 -178.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.896 HG22 ' H ' ' A' ' 70' ' ' ASP . 20.1 mm 75.87 -152.65 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.235 0 N-CA-C 103.441 -2.8 . . . . 0.0 103.441 -176.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.896 ' H ' HG22 ' A' ' 69' ' ' ILE . 7.2 m-20 -101.03 31.35 3.65 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 104.62 -2.363 . . . . 0.0 104.62 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' CYS . . . . . 0.436 ' O ' ' HB3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER -91.11 -67.67 0.84 Allowed 'General case' 0 C--N 1.352 0.696 0 N-CA-C 104.265 -2.495 . . . . 0.0 104.265 -176.37 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -76.8 -31.45 56.96 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 116.511 -2.075 . . . . 0.0 105.428 177.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -65.53 -76.7 0.31 Allowed Glycine 0 C--N 1.358 1.772 0 C-N-CA 118.506 -1.807 . . . . 0.0 113.381 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.428 HD12 ' CD2' ' A' ' 60' ' ' LEU . 15.4 mt -82.05 -25.15 34.87 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 116.382 -1.771 . . . . 0.0 111.235 -175.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.59 HH21 ' CG ' ' A' ' 114' ' ' ASP . 0.1 OUTLIER -71.09 -28.82 64.61 Favored 'General case' 0 C--N 1.364 1.198 0 C-N-CA 111.996 -3.882 . . . . 0.0 108.672 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 21.3 mm100 -63.53 -30.18 71.34 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 117.835 -1.546 . . . . 0.0 107.476 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 27.7 mmmt -69.27 -42.54 75.42 Favored 'General case' 0 C--N 1.36 1.033 0 O-C-N 124.584 1.177 . . . . 0.0 108.714 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' CYS . . . . . . . . . . . . . 86.8 m -58.49 -36.02 73.11 Favored 'General case' 0 C--N 1.348 0.527 0 C-N-CA 126.49 1.916 . . . . 0.0 108.436 -178.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -72.41 -47.94 45.21 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -90.13 24.84 2.35 Favored 'General case' 0 C--N 1.361 1.077 0 O-C-N 124.488 1.118 . . . . 0.0 111.132 -178.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -111.53 -65.59 1.16 Allowed 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 178.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 167.68 -22.92 0.11 Allowed Glycine 0 CA--C 1.532 1.156 0 CA-C-N 111.339 -2.664 . . . . 0.0 112.759 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 46.64 48.13 14.47 Favored 'General case' 0 C--N 1.364 1.229 0 C-N-CA 125.764 1.626 . . . . 0.0 108.726 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -63.45 -98.98 0.0 OUTLIER 'General case' 0 C--N 1.351 0.646 0 CA-C-N 112.149 -2.296 . . . . 0.0 106.845 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.67 -18.4 48.34 Favored Glycine 0 CA--C 1.536 1.397 0 CA-C-N 114.6 -1.182 . . . . 0.0 110.298 178.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 mt -60.72 106.59 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 124.117 1.913 . . . . 0.0 109.392 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.5 pp -104.61 131.45 52.01 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 108.725 -3.852 . . . . 0.0 102.12 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' HA ' ' A' ' 114' ' ' ASP . 2.5 tt -105.14 126.12 51.74 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 103.481 -2.785 . . . . 0.0 103.481 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' TYR . . . . . 0.419 ' CE1' ' HB2' ' A' ' 133' ' ' ASP . 1.3 m-30 -121.47 162.42 20.52 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 102.238 -3.245 . . . . 0.0 102.238 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 33.2 t -134.01 167.87 25.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 112.335 -2.211 . . . . 0.0 106.726 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 177.28 -158.54 24.14 Favored Glycine 0 C--N 1.343 0.932 0 C-N-CA 117.706 -2.188 . . . . 0.0 110.436 178.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.88 -112.77 4.07 Favored Glycine 0 C--N 1.35 1.361 0 CA-C-N 112.333 -1.934 . . . . 0.0 108.55 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 21.3 m120 67.97 -179.88 0.23 Allowed 'General case' 0 C--N 1.354 0.771 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 178.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.0 mp -134.61 -96.82 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.352 0.678 0 N-CA-C 104.684 -2.339 . . . . 0.0 104.684 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.8 m -81.61 92.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.358 0.937 0 CA-C-O 122.76 1.267 . . . . 0.0 110.152 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.34 -124.26 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.76 0 CA-C-N 111.669 -2.514 . . . . 0.0 109.115 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 97.8 -51.51 1.33 Allowed Glycine 0 C--N 1.352 1.441 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.85 71.59 2.21 Favored 'General case' 0 C--N 1.352 0.703 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLN . . . . . . . . . . . . . 16.2 tt0 -152.61 27.98 0.55 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 111.837 -2.438 . . . . 0.0 105.491 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -160.09 52.28 0.33 Allowed 'General case' 0 C--N 1.352 0.683 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' TRP . . . . . 0.479 ' H ' ' HD2' ' A' ' 102' ' ' PRO . 3.7 t-105 -172.95 -54.03 0.0 OUTLIER Pre-proline 0 N--CA 1.446 -0.634 0 CA-C-N 111.364 -2.653 . . . . 0.0 107.322 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.479 ' HD2' ' H ' ' A' ' 101' ' ' TRP . 52.9 Cg_exo -43.92 105.6 0.07 OUTLIER 'Trans proline' 0 C--N 1.39 2.732 0 C-N-CA 122.319 2.013 . . . . 0.0 109.497 -175.363 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' A' ' 107' ' ' ARG . 25.4 m-20 -77.64 1.15 20.64 Favored 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 111.648 -2.524 . . . . 0.0 109.687 -177.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.413 ' C ' ' H ' ' A' ' 107' ' ' ARG . 6.7 p -90.33 -48.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.35 0.624 0 C-N-CA 129.641 3.177 . . . . 0.0 110.847 -178.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -77.31 -42.46 36.76 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 104.03 -2.581 . . . . 0.0 104.03 178.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.45 -15.24 63.56 Favored 'General case' 0 C--N 1.357 0.905 0 CA-C-N 110.962 -2.835 . . . . 0.0 105.618 177.238 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.461 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 30.3 tpt180 -70.61 -47.51 59.79 Favored 'General case' 0 C--N 1.371 1.516 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 177.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.401 ' HA ' ' HB2' ' A' ' 111' ' ' MET . 3.3 m-85 -83.29 4.79 25.6 Favored 'General case' 0 C--N 1.362 1.117 0 O-C-N 125.741 1.901 . . . . 0.0 111.304 -174.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.428 ' HG2' HH11 ' A' ' 115' ' ' ARG . 32.9 ttpt -90.0 -57.56 2.81 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -177.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.62 -15.5 54.44 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 111.868 -2.424 . . . . 0.0 106.677 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.401 ' HB2' ' HA ' ' A' ' 108' ' ' PHE 0.317 32.6 mmt -88.08 -14.52 38.67 Favored 'General case' 0 C--N 1.372 1.567 0 O-C-N 124.09 0.869 . . . . 0.0 109.608 -179.362 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -147.37 -89.82 0.09 OUTLIER Glycine 0 C--N 1.348 1.199 0 C-N-CA 118.598 -1.763 . . . . 0.0 110.598 179.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.422 ' H ' ' H ' ' A' ' 114' ' ' ASP . 0.1 OUTLIER -158.9 -25.45 0.07 Allowed 'General case' 0 N--CA 1.433 -1.281 0 CA-C-N 111.221 -2.489 . . . . 0.0 110.953 -175.261 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.59 ' CG ' HH21 ' A' ' 75' ' ' ARG . 9.1 t70 -53.2 89.94 0.01 OUTLIER 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 126.156 2.884 . . . . 0.0 111.194 -175.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.428 HH11 ' HG2' ' A' ' 109' ' ' LYS . 0.2 OUTLIER -106.29 172.08 7.0 Favored 'General case' 0 C--N 1.328 -0.366 2 CA-C-N 104.43 -5.804 . . . . 0.0 102.426 176.989 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.17 138.83 14.91 Favored 'Isoleucine or valine' 0 C--N 1.35 0.621 0 C-N-CA 118.336 -1.346 . . . . 0.0 110.478 -177.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -138.57 107.4 5.96 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-N 113.509 -1.678 . . . . 0.0 106.848 -177.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -123.22 152.53 64.01 Favored Pre-proline 0 C--N 1.349 0.559 0 CA-C-N 111.364 -2.653 . . . . 0.0 104.646 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_exo -39.14 113.66 0.17 Allowed 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 124.545 3.497 . . . . 0.0 110.24 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.97 -20.33 2.32 Favored Glycine 0 CA--C 1.538 1.527 0 CA-C-N 110.299 -3.137 . . . . 0.0 108.948 -177.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . 0.253 3.2 p -79.02 163.9 57.73 Favored Pre-proline 0 CA--C 1.554 1.132 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' PRO . . . . . 0.402 ' O ' HG13 ' A' ' 125' ' ' VAL . 8.5 Cg_endo -49.71 168.47 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.161 0 C-N-CA 124.581 3.521 . . . . 0.0 111.284 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -66.06 -14.38 44.18 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 121.92 1.747 . . . . 0.0 109.983 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -128.1 68.04 1.35 Allowed 'General case' 0 C--N 1.351 0.672 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 177.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.457 ' C ' ' H ' ' A' ' 127' ' ' ILE . 21.5 m -42.62 -123.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.104 0 C-N-CA 129.867 3.267 . . . . 0.0 111.411 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.454 ' HA3' ' CD1' ' A' ' 59' ' ' LEU . . . -69.3 22.02 0.38 Allowed Glycine 0 CA--C 1.548 2.11 0 CA-C-N 115.088 -0.96 . . . . 0.0 114.271 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.457 ' H ' ' C ' ' A' ' 125' ' ' VAL . 50.1 mt -90.21 -64.59 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 C-N-CA 127.371 2.268 . . . . 0.0 107.245 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -75.48 -16.32 60.32 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 122.657 1.218 . . . . 0.0 108.647 -178.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ASP . . . . . 0.454 ' HB2' ' HA2' ' A' ' 126' ' ' GLY 0.278 2.1 m-20 -81.68 -50.84 8.83 Favored 'General case' 0 N--CA 1.436 -1.155 0 C-N-CA 128.278 2.631 . . . . 0.0 107.784 -179.335 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 3.8 pp -62.34 -20.39 64.32 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 117.821 -1.552 . . . . 0.0 108.717 178.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 8.5 tmtm? -80.45 -27.64 37.88 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 113.554 -1.657 . . . . 0.0 108.265 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 129' ' ' ASP . 1.9 mtpm? -67.25 -54.34 21.85 Favored 'General case' 0 C--N 1.356 0.889 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.419 ' HB2' ' CE1' ' A' ' 89' ' ' TYR 0.273 2.2 m-20 -74.3 -7.0 51.26 Favored 'General case' 0 C--N 1.357 0.911 0 CA-C-N 113.281 -1.782 . . . . 0.0 110.621 -176.848 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 53.0 tp -87.29 -30.53 20.8 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 176.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -90.18 4.07 51.58 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 114.361 -1.29 . . . . 0.0 109.608 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 56.8 mt -145.98 50.64 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 . . . . . 0 C--N 1.353 0.756 0 CA-C-N 113.391 -1.731 . . . . 0.0 111.87 -179.05 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.453 -0.294 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -158.89 164.0 36.08 Favored 'General case' 0 C--N 1.35 0.589 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.483 ' HD3' ' H ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -76.14 -169.75 1.23 Allowed 'General case' 0 C--N 1.346 0.456 0 CA-C-N 111.43 -2.623 . . . . 0.0 104.649 177.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -76.61 -179.52 5.33 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 104.985 -2.228 . . . . 0.0 104.985 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 m -150.12 94.4 2.14 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 101.629 -3.471 . . . . 0.0 101.629 -178.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.662 HG13 HG22 ' A' ' 34' ' ' VAL . 49.8 pt -122.74 158.63 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-N 109.24 -3.618 . . . . 0.0 105.763 -175.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.504 HG22 ' HB ' ' A' ' 35' ' ' VAL . 34.8 t -149.99 165.47 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.539 0 CA-C-N 111.026 -2.806 . . . . 0.0 106.214 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -141.46 119.21 11.76 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 102.154 -3.276 . . . . 0.0 102.154 177.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.61 178.23 48.72 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 112.834 -1.985 . . . . 0.0 112.512 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.668 HG11 ' HA ' ' A' ' 62' ' ' SER 0.291 43.7 t 64.09 -106.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 111.757 -2.221 . . . . 0.0 109.538 -178.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.451 HG12 HG12 ' A' ' 10' ' ' VAL . 3.4 pt -154.59 113.67 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.595 0 N-CA-C 105.677 -1.972 . . . . 0.0 105.677 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -96.46 -105.63 2.24 Favored Glycine 0 C--N 1.352 1.441 0 CA-C-N 112.361 -2.2 . . . . 0.0 109.916 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.3 t -161.11 159.21 28.82 Favored 'General case' 0 C--N 1.351 0.637 0 N-CA-C 106.014 -1.846 . . . . 0.0 106.014 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -149.54 100.72 3.02 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 110.782 -2.917 . . . . 0.0 103.222 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.445 ' H ' HD11 ' A' ' 22' ' ' ILE . 27.4 p -82.58 88.51 6.66 Favored 'General case' 0 C--N 1.354 0.764 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 -179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' HIS . . . . . . . . . . . . . 73.3 t60 -134.25 -50.74 0.81 Allowed 'General case' 0 C--N 1.346 0.452 0 CA-C-N 111.583 -2.553 . . . . 0.0 104.393 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.56 41.37 1.73 Allowed 'General case' 0 C--N 1.35 0.626 0 N-CA-C 105.02 -2.215 . . . . 0.0 105.02 179.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 44.3 t -135.87 -51.74 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.851 0 CA-C-N 113.367 -1.742 . . . . 0.0 108.683 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 73.91 101.8 0.08 OUTLIER Glycine 0 C--N 1.354 1.546 0 CA-C-N 113.747 -1.57 . . . . 0.0 110.15 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -145.94 -165.52 2.22 Favored 'General case' 0 C--N 1.353 0.741 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 -178.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -123.39 90.85 3.36 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 102.72 -3.067 . . . . 0.0 102.72 178.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.445 HD11 ' H ' ' A' ' 15' ' ' CYS . 4.1 pt -140.68 -41.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.702 0 CA-C-N 113.38 -1.736 . . . . 0.0 106.594 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.9 mt -108.67 70.86 0.76 Allowed 'General case' 0 C--N 1.352 0.715 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -93.15 -49.81 5.81 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-N 112.915 -1.948 . . . . 0.0 106.815 -178.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -145.88 -43.98 0.21 Allowed 'General case' 0 C--N 1.35 0.608 0 CA-C-N 113.308 -1.769 . . . . 0.0 106.535 -179.033 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -134.22 168.35 19.02 Favored 'General case' 0 C--N 1.352 0.703 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 -178.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.512 ' O ' HG21 ' A' ' 34' ' ' VAL . 8.8 t80 133.68 -52.83 0.01 OUTLIER 'General case' 0 C--N 1.355 0.816 0 CA-C-N 110.645 -2.98 . . . . 0.0 103.691 -179.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.436 ' H ' ' H ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -155.62 -12.67 0.11 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 112.476 -2.147 . . . . 0.0 106.932 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.436 ' H ' ' H ' ' A' ' 28' ' ' THR . 47.6 t30 -79.5 0.65 28.77 Favored 'General case' 0 CA--C 1.554 1.125 0 N-CA-C 105.281 -2.118 . . . . 0.0 105.281 176.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.2 -52.78 4.22 Favored 'General case' 0 C--N 1.365 1.243 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 128.66 17.02 1.96 Allowed Glycine 0 CA--C 1.537 1.459 0 CA-C-N 111.438 -2.619 . . . . 0.0 114.0 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 37.4 m-85 -64.16 165.33 9.41 Favored 'General case' 0 C--N 1.358 0.958 0 CA-C-O 123.179 1.466 . . . . 0.0 108.992 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -89.91 79.8 6.55 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-N 110.629 -2.987 . . . . 0.0 104.113 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.662 HG22 HG13 ' A' ' 6' ' ' ILE . 11.7 t -100.74 134.44 40.67 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 113.948 -1.478 . . . . 0.0 113.676 -178.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.504 ' HB ' HG22 ' A' ' 7' ' ' VAL . 10.1 t -120.29 145.89 25.95 Favored 'Isoleucine or valine' 0 C--N 1.352 0.687 0 CA-C-N 110.462 -3.063 . . . . 0.0 105.113 176.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 53.2 t-20 -127.28 92.85 3.59 Favored 'General case' 0 C--N 1.346 0.423 0 N-CA-C 102.855 -3.017 . . . . 0.0 102.855 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 tt -85.76 142.33 13.31 Favored 'Isoleucine or valine' 0 C--N 1.351 0.667 0 CA-C-N 112.211 -2.268 . . . . 0.0 106.442 -178.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.67 -173.88 1.03 Allowed Glycine 0 C--N 1.354 1.534 0 CA-C-N 111.219 -2.719 . . . . 0.0 114.574 -178.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.1 m -46.57 164.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.771 0 CA-C-N 110.402 -2.899 . . . . 0.0 113.21 -178.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.55 ' H ' HD13 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -67.5 136.84 55.22 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 111.173 -2.74 . . . . 0.0 107.32 -179.698 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 60.4 p -139.36 -170.59 0.24 Allowed Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 102.941 -2.985 . . . . 0.0 102.941 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -56.79 141.24 92.52 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 122.033 1.822 . . . . 0.0 107.383 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.3 mp0 -72.7 -16.34 61.68 Favored 'General case' 0 C--N 1.348 0.528 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.312 -178.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 21.3 mm-40 -84.13 -23.09 30.83 Favored 'General case' 0 CA--C 1.55 0.943 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.4 t -90.64 -22.67 6.22 Favored 'Isoleucine or valine' 0 C--N 1.348 0.542 0 CA-C-N 113.622 -1.626 . . . . 0.0 108.759 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.43 ' HA ' ' HB3' ' A' ' 49' ' ' ALA . 0.1 OUTLIER -87.06 -15.68 37.84 Favored 'General case' 0 C--N 1.359 0.998 0 N-CA-C 104.543 -2.391 . . . . 0.0 104.543 179.113 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -76.84 -41.26 32.51 Favored 'Isoleucine or valine' 0 C--N 1.36 1.032 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 179.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -70.6 -35.0 72.77 Favored 'General case' 0 C--N 1.352 0.705 0 CA-C-N 113.739 -1.573 . . . . 0.0 106.806 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.43 ' HB3' ' HA ' ' A' ' 46' ' ' PHE . . . -75.85 -9.4 58.57 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.138 -2.301 . . . . 0.0 107.416 178.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -90.23 -17.3 27.74 Favored 'General case' 0 C--N 1.364 1.21 0 O-C-N 123.816 0.697 . . . . 0.0 109.948 178.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mp -66.24 -44.88 91.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 N-CA-C 104.275 -2.491 . . . . 0.0 104.275 178.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -77.26 -47.35 20.35 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 112.752 -2.022 . . . . 0.0 108.015 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.533 ' C ' ' H ' ' A' ' 55' ' ' ALA . 4.6 m -90.51 56.08 3.21 Favored 'General case' 0 C--N 1.356 0.88 0 C-N-CA 126.279 1.831 . . . . 0.0 106.842 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -89.52 29.13 1.17 Allowed 'General case' 0 CA--C 1.551 1.01 0 CA-C-N 113.273 -1.785 . . . . 0.0 106.985 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.533 ' H ' ' C ' ' A' ' 53' ' ' THR . . . -63.79 126.66 28.34 Favored 'General case' 0 CA--C 1.493 -1.234 0 C-N-CA 131.275 3.83 . . . . 0.0 106.108 177.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -62.84 -10.78 14.44 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 111.065 -2.789 . . . . 0.0 106.552 177.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -136.06 140.71 43.99 Favored 'General case' 0 C--N 1.372 1.578 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 6.9 mt -149.53 80.95 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 104.698 -2.334 . . . . 0.0 104.698 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.454 ' CD1' ' HA3' ' A' ' 126' ' ' GLY . 9.3 tt -81.89 99.22 8.93 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 178.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.428 ' CD2' HD12 ' A' ' 74' ' ' LEU . 1.1 mp -83.22 96.43 8.45 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.82 80.35 7.31 Favored 'General case' 0 C--N 1.351 0.672 0 CA-C-N 110.772 -2.922 . . . . 0.0 103.202 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.668 ' HA ' HG11 ' A' ' 10' ' ' VAL . 29.4 t -95.71 139.97 31.18 Favored 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 110.812 -2.904 . . . . 0.0 107.501 -175.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 11.2 mp -108.82 56.3 0.62 Allowed 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 110.484 -3.053 . . . . 0.0 105.429 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 66.32 95.57 0.06 Allowed 'General case' 0 C--N 1.357 0.897 0 CA-C-N 112.606 -2.088 . . . . 0.0 107.867 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 177.7 137.41 2.74 Favored Glycine 0 C--N 1.353 1.492 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.539 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.452 ' HG2' ' H ' ' A' ' 67' ' ' GLY . 19.4 tt0 92.31 172.73 0.02 OUTLIER 'General case' 0 C--N 1.358 0.957 0 N-CA-C 105.258 -2.127 . . . . 0.0 105.258 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.452 ' H ' ' HG2' ' A' ' 66' ' ' GLN . . . -54.05 98.32 0.04 OUTLIER Glycine 0 C--N 1.359 1.808 0 O-C-N 124.566 1.166 . . . . 0.0 112.71 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.401 ' O ' ' HB3' ' A' ' 71' ' ' CYS . 83.6 mt-10 46.85 54.14 9.46 Favored 'General case' 0 C--N 1.361 1.07 0 N-CA-C 105.172 -2.159 . . . . 0.0 105.172 -178.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.896 HG22 ' H ' ' A' ' 70' ' ' ASP . 20.1 mm 75.87 -152.65 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.235 0 N-CA-C 103.441 -2.8 . . . . 0.0 103.441 -176.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.896 ' H ' HG22 ' A' ' 69' ' ' ILE . 7.2 m-20 -101.03 31.35 3.65 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 104.62 -2.363 . . . . 0.0 104.62 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' CYS . . . . . 0.436 ' O ' ' HB3' ' A' ' 75' ' ' ARG . 0.0 OUTLIER -91.11 -67.67 0.84 Allowed 'General case' 0 C--N 1.352 0.696 0 N-CA-C 104.265 -2.495 . . . . 0.0 104.265 -176.37 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -76.8 -31.45 56.96 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 116.511 -2.075 . . . . 0.0 105.428 177.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -65.53 -76.7 0.31 Allowed Glycine 0 C--N 1.358 1.772 0 C-N-CA 118.506 -1.807 . . . . 0.0 113.381 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.428 HD12 ' CD2' ' A' ' 60' ' ' LEU . 15.4 mt -82.05 -25.15 34.87 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 116.382 -1.771 . . . . 0.0 111.235 -175.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.59 HH21 ' CG ' ' A' ' 114' ' ' ASP . 0.1 OUTLIER -71.09 -28.82 64.61 Favored 'General case' 0 C--N 1.364 1.198 0 C-N-CA 111.996 -3.882 . . . . 0.0 108.672 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 21.3 mm100 -63.53 -30.18 71.34 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 117.835 -1.546 . . . . 0.0 107.476 179.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 27.7 mmmt -69.27 -42.54 75.42 Favored 'General case' 0 C--N 1.36 1.033 0 O-C-N 124.584 1.177 . . . . 0.0 108.714 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' CYS . . . . . . . . . . . . . 86.8 m -58.49 -36.02 73.11 Favored 'General case' 0 C--N 1.348 0.527 0 C-N-CA 126.49 1.916 . . . . 0.0 108.436 -178.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -72.41 -47.94 45.21 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -178.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -90.13 24.84 2.35 Favored 'General case' 0 C--N 1.361 1.077 0 O-C-N 124.488 1.118 . . . . 0.0 111.132 -178.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -111.53 -65.59 1.16 Allowed 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 104.663 -2.347 . . . . 0.0 104.663 178.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 167.68 -22.92 0.11 Allowed Glycine 0 CA--C 1.532 1.156 0 CA-C-N 111.339 -2.664 . . . . 0.0 112.759 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 46.64 48.13 14.47 Favored 'General case' 0 C--N 1.364 1.229 0 C-N-CA 125.764 1.626 . . . . 0.0 108.726 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -63.45 -98.98 0.0 OUTLIER 'General case' 0 C--N 1.351 0.646 0 CA-C-N 112.149 -2.296 . . . . 0.0 106.845 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.67 -18.4 48.34 Favored Glycine 0 CA--C 1.536 1.397 0 CA-C-N 114.6 -1.182 . . . . 0.0 110.298 178.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 mt -60.72 106.59 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.945 0 CA-C-O 124.117 1.913 . . . . 0.0 109.392 -179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.5 pp -104.61 131.45 52.01 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 108.725 -3.852 . . . . 0.0 102.12 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' HA ' ' A' ' 114' ' ' ASP . 2.5 tt -105.14 126.12 51.74 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 103.481 -2.785 . . . . 0.0 103.481 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . 0.419 ' CE1' ' HB2' ' A' ' 133' ' ' ASP . 1.3 m-30 -121.47 162.42 20.52 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 102.238 -3.245 . . . . 0.0 102.238 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 33.2 t -134.01 167.87 25.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-N 112.335 -2.211 . . . . 0.0 106.726 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 177.28 -158.54 24.14 Favored Glycine 0 C--N 1.343 0.932 0 C-N-CA 117.706 -2.188 . . . . 0.0 110.436 178.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.88 -112.77 4.07 Favored Glycine 0 C--N 1.35 1.361 0 CA-C-N 112.333 -1.934 . . . . 0.0 108.55 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 21.3 m120 67.97 -179.88 0.23 Allowed 'General case' 0 C--N 1.354 0.771 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 178.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.0 mp -134.61 -96.82 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.352 0.678 0 N-CA-C 104.684 -2.339 . . . . 0.0 104.684 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.8 m -81.61 92.28 2.2 Favored 'Isoleucine or valine' 0 C--N 1.358 0.937 0 CA-C-O 122.76 1.267 . . . . 0.0 110.152 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 15.8 m -93.34 -124.26 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.76 0 CA-C-N 111.669 -2.514 . . . . 0.0 109.115 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 97.8 -51.51 1.33 Allowed Glycine 0 C--N 1.352 1.441 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.85 71.59 2.21 Favored 'General case' 0 C--N 1.352 0.703 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 178.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLN . . . . . . . . . . . . . 16.2 tt0 -152.61 27.98 0.55 Allowed 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 111.837 -2.438 . . . . 0.0 105.491 179.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -160.09 52.28 0.33 Allowed 'General case' 0 C--N 1.352 0.683 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' TRP . . . . . 0.479 ' H ' ' HD2' ' A' ' 102' ' ' PRO . 3.7 t-105 -172.95 -54.03 0.0 OUTLIER Pre-proline 0 N--CA 1.446 -0.634 0 CA-C-N 111.364 -2.653 . . . . 0.0 107.322 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.479 ' HD2' ' H ' ' A' ' 101' ' ' TRP . 52.9 Cg_exo -43.92 105.6 0.07 OUTLIER 'Trans proline' 0 C--N 1.39 2.732 0 C-N-CA 122.319 2.013 . . . . 0.0 109.497 -175.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' A' ' 107' ' ' ARG . 25.4 m-20 -77.64 1.15 20.64 Favored 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 111.648 -2.524 . . . . 0.0 109.687 -177.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.413 ' C ' ' H ' ' A' ' 107' ' ' ARG . 6.7 p -90.33 -48.09 14.38 Favored 'Isoleucine or valine' 0 C--N 1.35 0.624 0 C-N-CA 129.641 3.177 . . . . 0.0 110.847 -178.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -77.31 -42.46 36.76 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 104.03 -2.581 . . . . 0.0 104.03 178.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.45 -15.24 63.56 Favored 'General case' 0 C--N 1.357 0.905 0 CA-C-N 110.962 -2.835 . . . . 0.0 105.618 177.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.461 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 30.3 tpt180 -70.61 -47.51 59.79 Favored 'General case' 0 C--N 1.371 1.516 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 177.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.401 ' HA ' ' HB2' ' A' ' 111' ' ' MET . 3.3 m-85 -83.29 4.79 25.6 Favored 'General case' 0 C--N 1.362 1.117 0 O-C-N 125.741 1.901 . . . . 0.0 111.304 -174.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.428 ' HG2' HH11 ' A' ' 115' ' ' ARG . 32.9 ttpt -90.0 -57.56 2.81 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -177.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.62 -15.5 54.44 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 111.868 -2.424 . . . . 0.0 106.677 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.401 ' HB2' ' HA ' ' A' ' 108' ' ' PHE 0.317 32.6 mmt -88.08 -14.52 38.67 Favored 'General case' 0 C--N 1.372 1.567 0 O-C-N 124.09 0.869 . . . . 0.0 109.608 -179.362 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -147.37 -89.82 0.09 OUTLIER Glycine 0 C--N 1.348 1.199 0 C-N-CA 118.598 -1.763 . . . . 0.0 110.598 179.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.422 ' H ' ' H ' ' A' ' 114' ' ' ASP . 0.1 OUTLIER -158.9 -25.45 0.07 Allowed 'General case' 0 N--CA 1.433 -1.281 0 CA-C-N 111.221 -2.489 . . . . 0.0 110.953 -175.261 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.59 ' CG ' HH21 ' A' ' 75' ' ' ARG . 9.1 t70 -53.2 89.94 0.01 OUTLIER 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 126.156 2.884 . . . . 0.0 111.194 -175.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.428 HH11 ' HG2' ' A' ' 109' ' ' LYS . 0.2 OUTLIER -106.29 172.08 7.0 Favored 'General case' 0 C--N 1.328 -0.366 2 CA-C-N 104.43 -5.804 . . . . 0.0 102.426 176.989 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 11.0 p -150.17 138.83 14.91 Favored 'Isoleucine or valine' 0 C--N 1.35 0.621 0 C-N-CA 118.336 -1.346 . . . . 0.0 110.478 -177.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -138.57 107.4 5.96 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-N 113.509 -1.678 . . . . 0.0 106.848 -177.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -123.22 152.53 64.01 Favored Pre-proline 0 C--N 1.349 0.559 0 CA-C-N 111.364 -2.653 . . . . 0.0 104.646 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_exo -39.14 113.66 0.17 Allowed 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 124.545 3.497 . . . . 0.0 110.24 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.97 -20.33 2.32 Favored Glycine 0 CA--C 1.538 1.527 0 CA-C-N 110.299 -3.137 . . . . 0.0 108.948 -177.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . 0.253 3.2 p -79.02 163.9 57.73 Favored Pre-proline 0 CA--C 1.554 1.132 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . 0.402 ' O ' HG13 ' A' ' 125' ' ' VAL . 8.5 Cg_endo -49.71 168.47 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.161 0 C-N-CA 124.581 3.521 . . . . 0.0 111.284 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -66.06 -14.38 44.18 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 121.92 1.747 . . . . 0.0 109.983 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -128.1 68.04 1.35 Allowed 'General case' 0 C--N 1.351 0.672 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 177.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.457 ' C ' ' H ' ' A' ' 127' ' ' ILE . 21.5 m -42.62 -123.81 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.104 0 C-N-CA 129.867 3.267 . . . . 0.0 111.411 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.454 ' HA3' ' CD1' ' A' ' 59' ' ' LEU . . . -69.3 22.02 0.38 Allowed Glycine 0 CA--C 1.548 2.11 0 CA-C-N 115.088 -0.96 . . . . 0.0 114.271 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.457 ' H ' ' C ' ' A' ' 125' ' ' VAL . 50.1 mt -90.21 -64.59 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 C-N-CA 127.371 2.268 . . . . 0.0 107.245 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -75.48 -16.32 60.32 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 122.657 1.218 . . . . 0.0 108.647 -178.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ASP . . . . . 0.454 ' HB2' ' HA2' ' A' ' 126' ' ' GLY 0.278 2.1 m-20 -81.68 -50.84 8.83 Favored 'General case' 0 N--CA 1.436 -1.155 0 C-N-CA 128.278 2.631 . . . . 0.0 107.784 -179.335 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 3.8 pp -62.34 -20.39 64.32 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 117.821 -1.552 . . . . 0.0 108.717 178.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 8.5 tmtm? -80.45 -27.64 37.88 Favored 'General case' 0 CA--C 1.547 0.827 0 CA-C-N 113.554 -1.657 . . . . 0.0 108.265 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 129' ' ' ASP . 1.9 mtpm? -67.25 -54.34 21.85 Favored 'General case' 0 C--N 1.356 0.889 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.419 ' HB2' ' CE1' ' A' ' 89' ' ' TYR 0.273 2.2 m-20 -74.3 -7.0 51.26 Favored 'General case' 0 C--N 1.357 0.911 0 CA-C-N 113.281 -1.782 . . . . 0.0 110.621 -176.848 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LEU . . . . . . . . . . . . . 53.0 tp -87.29 -30.53 20.8 Favored 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 105.028 -2.212 . . . . 0.0 105.028 176.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -90.18 4.07 51.58 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 114.361 -1.29 . . . . 0.0 109.608 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 56.8 mt -145.98 50.64 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 . . . . . 0 C--N 1.353 0.756 0 CA-C-N 113.391 -1.731 . . . . 0.0 111.87 -179.05 . . . . . . . . 0 0 . 1 stop_ save_